抗表皮生长因子受体单克隆抗体——西妥昔单抗在结直肠癌治疗中的临床进展

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (7): 837-840.

• 综述与讲座 • 上一篇

抗表皮生长因子受体单克隆抗体——西妥昔单抗在结直肠癌治疗中的临床进展

吴亮, 郑民华

上海交通大学医学院附属瑞金医院外科, 上海市微创外科临床医学中心, 上海 200025

收稿日期:2007-11-12 修回日期:2008-04-23 出版日期:2008-07-26 发布日期:2020-10-14
通讯作者: 郑民华,男,教授,博士生导师。E-mail:zmhtiger@yeah.net
作者简介:吴亮,男,博士研究生。Tel:13564191213 E-mail:wuliang-25@yahoo.com.cn

Clinical progress of anti-epidermal growth factor receptor antibody, cetuximab, in the treatment of colorectal cancer

WU Liang, ZHENG Min-hua

Department of Surgery, Affiliated Ruijin Hospital, Medical College of Shanghai Jiaotong University Shanghai Minimally Invasive Surgery Center, Shanghai 200025,China

Received:2007-11-12 Revised:2008-04-23 Online:2008-07-26 Published:2020-10-14

摘要/Abstract

摘要： 最近,一些临床试验的结果肯定了西妥昔单抗(cetuximab)作为一种表皮生长因子受体(EGFR)单克隆抗体在结直肠肿瘤的治疗作用。本文从转移性结直肠癌治疗的角度综述西妥昔单抗这一EGFR抗体的临床观察结果,回顾分析了多篇近年发表的关于西妥昔单抗在结直肠癌和其它恶性肿瘤临床应用的文献。西妥昔单抗在转移性结直肠肿瘤的无进展生存期的延长上获得了肯定的疗效(3.9月vs2.56月,P<0.01)。然而,在作为第二线治疗时,西妥昔单抗与依立替康的联合治疗对比依立替康单药治疗并没有使平均生存期得到延长。在副作用方面,痤疮样皮疹的严重程度可以预示肿瘤对西妥昔单抗的应答强弱,外用糖皮质激素和润肤剂可以治疗这一副作用。低镁血症是该药引起的一个比较特殊的副作用,使用静脉补镁是治疗低镁血症的有效方法。

关键词: 西妥昔单抗, 结直肠癌, 表皮生长因子受体, 痤疮样皮疹, 低镁血症

Abstract: Recent clinical trials suggested that epidermal growth factor receptor (EGFR) targeted agents could benefit many patients with colorectal cancer.This article reviews the clinical efficacy of cetuximab, which is an antibody directed at the EGFR, in the treatment of metastatic colorectal carcinoma.Several articles about EGFR-targeted therapies in metastatic colorectal carcinoma and other solid tumors were reviewed.Cetuximab showed the increase in progressionfree survival (3.98 months vs 2.56 months, P< 0.01).However, it did not show any advantage in mean survival time.For side effects, the severity of acne-like rash implied the response and the cetuximab therapy could be pursued by applying topical corticosteroids and emollients.Hypomagnesaemia, as a relatively special side effect, can be treated with intravenous magnesium sulfate.

Key words: cetuximab, colorectal cancer, epidermal growth factor receptor, acneiform rash, hypomagnesaemia

中图分类号:

R735

吴亮, 郑民华. 抗表皮生长因子受体单克隆抗体——西妥昔单抗在结直肠癌治疗中的临床进展[J]. 中国临床药理学与治疗学, 2008, 13(7): 837-840.

WU Liang, ZHENG Min-hua. Clinical progress of anti-epidermal growth factor receptor antibody, cetuximab, in the treatment of colorectal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(7): 837-840.

参考文献

[1] Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy[J]. Cancer Lett, 2007, 254(2): 165-177.
[2] Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer [J]. Clin Ther, 2005, 27(6): 684-694.
[3] Rocha-Lima CM, Soares HP, Raez LE, et al. EGFR Targeting of Solid Tumors[J]. Cancer Control, 2007, 14(3): 295-304.
[4] Tamura T. Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors[J]. Nippon Geka Gakkai Zasshi, 2002, 103(2): 233-236.
[5] Tortora G, Gelardi T, Ciardiello F, et al. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy [J]. Int J Biol Markers, 2007, 22(1 Suppl 4): S47-52.
[6] Cerea G, Ricotta R, Schiavetto I, et al. Cetuximab for treatment of metastatic colorectal cancer[J]. Ann Oncol, 2006, 17(Suppl 7): vii66-vii67.
[7] HarrisM. Monoclonal antibodies as therapeutic agents for cancer[J]. Lancet Oncol, 2004, 5(5): 292-302.
[8] Zhang W, Gordon M, Lenz HJ. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies[J]. AnnMed, 2006, 38(8): 545-551.
[9] Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer[J]. N Engl JMed, 2004, 351(4): 337-345.
[10] Gebbia V, Del Prete S, Borsellino N, et al. Efficacy and safety of cetuximab irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience[J]. Clin Colorectal Cancer, 2006, 5(6): 422-428.
[11] Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J]. J Clin Oncol, 2004, 22(7): 1201-1208.
[12] Tscharner GG, Buhler S, Borner M, et al. Grover's disease induced by cetuximab[J]. Dermatology, 2006, 213 (1): 37-39.
[13] Chong G, Cunningham D. The role of cetuximab in the therapy of previously treated advanced colorectal cancer [J]. Semin Oncol, 2005, 32(6 Suppl 9): S55-58.
[14] Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines[J]. J Clin Oncol, 2006, 24(30): 4914-4921.
[15] Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody[J]. Drugs Today (Barc), 2005, 41(2): 107-127.
[16] Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer [J]. Clin Colorectal Cancer, 2006, 6(2): 152-156.
[17] Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia[J]. J Natl Cancer Inst, 2005, 97(16): 1221-1224.
[18] Galizia G, Lieto E, De Vita F, et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer[J]. Oncogene, 2007, 26(25): 3654-3660.

抗表皮生长因子受体单克隆抗体——西妥昔单抗在结直肠癌治疗中的临床进展

Clinical progress of anti-epidermal growth factor receptor antibody, cetuximab, in the treatment of colorectal cancer

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[2]	卫真真, 隋华, 姜宇朗, 孙明瑜, 闫化茹, 王子元. 左金丸联合西妥昔单抗诱导KRAS突变肠癌细胞铁死亡作用研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 130-137.
[3]	吴先闯, 刘瑜新, 牛玉季, 赫锦锦, 乔辉, 张蕾蕾. 肝细胞癌中DCLK1转录调控的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1241-1246.
[4]	周广琛, 刘怡希, 郑云. 结直肠癌和microRNA：研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 575-587.
[5]	李岩岩, 方骁杰, 尹鑫, 孙曦, 饶春晖. circZNF124通过靶向miR-4262调控结直肠癌SW620细胞增殖、迁移及侵袭的机制研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1231-1239.
[6]	鲁琼, 朱海宏, 戚听听, 李国华, 滕欣琪, 屈强, 屈健. OCTN2基因多态性影响结直肠癌奥沙利铂化疗敏感性[J]. 中国临床药理学与治疗学, 2021, 26(4): 401-407.
[7]	张德志, 刘猛, 朱少功, 刘桂举, 季节. XELOX方案对比卡培他滨单药方案在老年结直肠癌患者术后辅助化疗中的疗效及安全性探讨[J]. 中国临床药理学与治疗学, 2020, 25(8): 926-936.
[8]	王子元, 孙明瑜. 长链非编码RNA在结直肠癌耐药中的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(7): 796-802.
[9]	石莉莉, 刘兴安, 单国用. 阿帕替尼后线治疗标准方案失败的晚期结直肠癌的疗效和安全性及疗效预测因子的初步分析[J]. 中国临床药理学与治疗学, 2020, 25(12): 1388-1394.
[10]	李荣振，梅家转，夏云展，季节. 真实世界中R0切除术后结直肠癌患者接受卡培他滨为基础辅助化疗的预后影响因素及安全性探讨[J]. 中国临床药理学与治疗学, 2019, 24(6): 704-711.
[11]	乔大伟，李玉芳，肖云，姜礼双，卜平. 半枝莲抗结直肠癌及其转移机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 332-336.
[12]	白艳，郑晓永，杨雅阁，方立峰. 程序性死亡配体1基因遗传变异对术后结直肠癌患者接受5-FU为基础辅助化疗预后的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 180-187.
[13]	李晓洁，张胜威，王华胜，王东，梅家转，邓业巍. VEGF-A基因多态性对接受氟尿嘧啶为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2018, 23(8): 900-904.
[14]	胡洋，李智星，王果，朱院山. 长链非编码RNA与结直肠癌耐药的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(4): 456-463.
[15]	张洋，陈志康，郭雄，王雯. 雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗的安全性研究[J]. 中国临床药理学与治疗学, 2018, 23(3): 313-318.